Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1 - 27/10/20
pages | 18 |
Iconographies | 4 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | Biomarkers are available for patients screening in anti-PD-1/PD-L1 therapy. |
• | IHC-assessed PD-L1 is approved as concomitant diagnostics for PD-1/PD-L1 blockade. |
• | MSI/dMMR and TMB-H are applied as site-agnostic biomarkers for Keytruda in solid tumors. |
• | Increasing numbers of more convenient and effective biomarkers are being developed. |
Abstract |
Rapidly increasing usages of immune checkpoint therapy for cancer treatment, particularly monoclonal antibodies that target programmed cell death-1 (PD-1) and its ligand PD-L1, have been achieved due to startling durable therapeutic efficacy with limited toxicity. The therapeutics significantly prolonged the overall survival and progression free survival of patients across multiple cancer types. However, the objective response rate of patients receiving this kind of treatment is substantially low. Therefore, it is of great importance to exploit reliable biomarkers that can robustly predict the therapeutic effects. Several biomarkers have been characterized for the selection of patients, which is mainly based on immunological and genetic criteria. Herein, we focus on the current progress regarding the biomarkers for anti-PD-1/PD-L1 therapy.
Le texte complet de cet article est disponible en PDF.Keywords : PD-1, PD-L1, Immune checkpoint therapy, Biomarker, Cancer
Plan
Vol 130
Article 110621- octobre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?